Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. QGEN

Go back to Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial

Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor Fitzgerald

September 26, 2018 9:33 AM EDT

Cantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.

Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More

Aldeyra Therapeutics (ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial

September 26, 2018 7:33 AM EDT

Aldeyra Therapeutics (NASDAQ: ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical Trial

... More